Atezolizumab is a humanized IgG1 monoclonal anti-programmed death-ligand 1 (PD-L1) antibody that has been approved by the U.S Food Drug Administration (FDA) for various neoplastic conditions either as a single agent or in combination with other chemotherapeutic agents. Atezolizumab is a drug that is used in the management and treatment of various neoplastic conditions. It is in the monoclonal antibody class of medications. This activity covers the indications, contraindications, adverse events, and other therapeutic factors clinicians need to know to drive patient outcomes effectively.

**Objectives:**
- Summarize mechanism of action of atezolizumab.
- Describe the adverse effects of atezolizumab.
- Review the pharmacokinetics and monitoring for immune-mediated adverse reactions related to atezolizumab.
- Outline the importance of an interprofessional team approach and care coordination when treating patients with atezolizumab.